Startseite Crystal structure of (5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl furan-2-carboxylate, C10H7FN2O5
Artikel Open Access

Crystal structure of (5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl furan-2-carboxylate, C10H7FN2O5

  • Xiaowei Yan , Dongjian Zhu , Xing Zhong und Sujuan Wang EMAIL logo
Veröffentlicht/Copyright: 18. Juni 2018

Abstract

C10H7FN2O5, monoclinic, P21/n (no. 14), a = 8.5781(17) Å, b = 5.3121(11) Å, c = 23.578(5) Å, β = 96.68(3)°, V = 1067.1(4) Å3, Z = 4, Rgt(F) = 0.0375, wRref(F2) = 0.1138, T = 293(2) K.

CCDC no.: 1847076

The title crystal structure is shown using a ball-and-stick scheme in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Needle, colorless
Size:0.48 × 0.21 × 0.14 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.14 mm−1
Diffractometer, scan mode:Bruker Apex, ω-scans
θmax, completeness:25°, >99%
N(hkl)measured, N(hkl)unique, Rint:7928, 1940, 0.045
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 1340
N(param)refined:163
Programs:Bruker programs [1], SHELX [2], Diamond [3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
F10.08872(17)0.7588(2)0.03503(6)0.0802(5)
O10.55122(19)0.3048(3)0.34117(6)0.0671(5)
O20.35433(19)0.0187(3)0.26793(6)0.0627(4)
O30.42085(16)0.2430(2)0.19354(5)0.0519(4)
O40.2640(2)0.5826(3)−0.04734(7)0.0805(5)
O50.45833(18)−0.0507(3)0.06935(6)0.0598(4)
N10.2859(2)0.2236(3)0.10285(6)0.0500(4)
N20.3555(2)0.2641(3)0.01112(6)0.0527(5)
H2A0.40580.2067−0.01560.063*
C10.6159(3)0.5609(4)0.27368(9)0.0595(6)
H1A0.62320.63450.23830.071*
C20.6882(3)0.6460(5)0.32696(10)0.0708(6)
H2B0.75310.78580.33350.085*
C30.6460(3)0.4884(5)0.36587(11)0.0741(7)
H3A0.67720.50170.40490.089*
C40.5346(2)0.3534(4)0.28382(8)0.0472(5)
C50.4287(2)0.1872(4)0.24948(8)0.0465(5)
C60.3025(3)0.1047(4)0.15796(8)0.0534(5)
H6A0.3342−0.06950.15470.064*
H6B0.20370.10880.17420.064*
C70.1909(2)0.4327(4)0.09361(9)0.0544(5)
H7A0.13380.48910.12230.065*
C80.1801(3)0.5531(4)0.04454(9)0.0562(5)
C90.2663(3)0.4776(4)−0.00171(8)0.0552(5)
C100.3730(2)0.1339(4)0.06143(8)0.0483(5)

Source of materials

The title compound was prepared by typical esterification reaction via acyl chloride. Reacting 5-fluoro-1,3-bis(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione with furan-2-carbonyl chloride in ice bath under the assistance of triethylamine for 24 h gave the crude product, than dissolved in ethyl acetate, washing with 20 mL 5% Na2CO3 solution, and than extracting the aqueous phase twice through ethyl acetate. After washing the organic phase by a saturated NaCl solution, the organic phase was finally collected and dried with anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was separated by column chromatography (PE:EA = 3:1) to afford the title compound with moderate yield. Colorless needle crystals were obtained and recrystallized in acetone and CH3OH mixed solvent at room temperature for 15 days.

Experimental details

All hydrogen atoms were positioned geometrically and allowed to ride on their parent atoms.

Comment

5-Fluorouracil (5-FU) as an antimetabolite has been discovered in 1956 and comes into medical use for anticancer therapy since 1962 [4], [5], [6]. Although clinically valuable and effective, 5-FU discloses off target side-effects in the gastrointestinal tract and bone marrow that may pose severe problems during therapy [7]. To improve bioavailability of 5-FU, the prodrug approach was recently explored for its delivery, notably by chemically modifying with small molecules like glucoside [8], peptide [9], [10], sulfonyl [11], ester [12], and so on, that in most instances improved anticancer potency and therapeutic value of 5-FU. Inspired by the study on linking 5-FU with thiophenecarboxylic acid through esterification reaction as a anticancer photosensitizer [12], we designed the title compound bearing ester of furancarboxylic acid. By multi-step reactions the title compound was obtained with moderate yield.

The asymmetric unit of the title structure contains one molecule (Figure). The bond lengths and angles are in the normal ranges. Both the hexacyclic-ring and the pentacyclic-ring in the structure are planar with mean deviation of 0.0022(2) Å and 0.0018(8) Å, respectively, and the dihedral angle between the two rings is 76.59(6)°, indicating they are nearly perpendicular to one another.

Award Identifier / Grant number: 21603064

Funding statement: We thank the National Natural Science Foundation of China (21603064), Natural Science Foundation of Guangxi (2016GXNSFBA380002), the Middle-aged and Young Teachers’ Basic Ability Promotion Project of Guangxi (2017KY0649), the Doctor’s Scientific Research Foundation of Hezhou University (HZUBS201507).

References

Bruker. APEX3 and SAINT. Bruker AXS Inc., Madison, WI, USA (2012).Suche in Google Scholar

Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

Brandenburg, K.: DIAMOND. Visual Crystal Structure Information System. Version 3.2i. Crystal Impact, Bonn, Germany (2012).Suche in Google Scholar

Cohen, S. S.; Flaks, J. G.; Barner, H. D.; Loeb, M. R.; Lichtenstein, J.: The mode of action of 5-fluorouracil and its derivatives. Proc. Natl. Acad. Sci. USA 44 (1958) 1004–1012.10.1073/pnas.44.10.1004Suche in Google Scholar PubMed PubMed Central

Curreri, A. R.; Ansfield, F. J.; McIver, F. A.; Waisman, H. A.; Heidelberger, C.: Clinical studies with 5-fluorouracil. Cancer Res. 18 (1958) 478–484.Suche in Google Scholar

Diasio, R. B.; Harris, B. E.: Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16 (1989) 215–237.10.2165/00003088-198916040-00002Suche in Google Scholar PubMed

Longley, D. B.; Harkin, D. P.; Johnston, P. G.: 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3 (2003) 330–338.10.1038/nrc1074Suche in Google Scholar PubMed

Szymańska-Michalak, A.; Wawrzyniak, D.; Framski, G.; Kujda, M.; Zgola, P.; Stawinski, J.; Barciszewski, J.; Boryski, J.; Kraszewski, A.: New 3′-O-aromatic acyl-5-fluoro-2′-deoxyuridine derivatives as potential anticancer agents. Euro. J. Med. Chem. 115 (2016) 41–52.10.1016/j.ejmech.2016.03.010Suche in Google Scholar PubMed

Yin, P.; Hu, M. L.; Yan, X. W.; Wang, S.; Miao, Q.; Chang, X. Q.; Zhao, K. J.: Synthesis, crystal structure and anticarcinogenic activity of four 5-fluorouracil-dipeptide derivatives. Acta Chim. Sinica 66 (2008) 1693–1699.Suche in Google Scholar

Yan, X. W.; Hu, M. L.; Miao, Q.; Wang, S.; Zhao, K. J.: The synthesis and anticancer activities of peptide 5-fluorouracil derivatives. J. Chem. Res. S 4 (2009) 261–264.10.3184/030823409X431364Suche in Google Scholar

Yan, X. W.; Hou, Y.; Chen, F.; Zhao, K. J.; Hu, M. L.: Synthesis and structure-antitumor activity relationship of sulfonyl 5-fluorouracilderivates. Phosphorus, Sulfur Silicon Relat. Elem. 185 (2010) 158–164.10.1080/10426500902754260Suche in Google Scholar

Li, M. R.; Cai, X. Q.; Zhu, Y. F.; Liu, K. G.; Hu, M. L.: Synthesis and biological evaluation of novel coupling derivatives of photosensitizer and 5-fluorouracil as antineoplastic agents. Acta Chim. Sinica 69 (2011) 425–430.Suche in Google Scholar

Received: 2018-03-01
Accepted: 2018-06-04
Published Online: 2018-06-18
Published in Print: 2018-08-28

©2018 Xiaowei Yan et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. Crystal structure of 2-amino-4-(2,4-dinitrophenyl)-3-cyano-7,7-dimethyl-5-oxo-4H-5,6,7,8-tetrahydrobenzo-pyran, C18H16N4O6
  3. Crystal structure of catena-poly[(μ3-5-carboxy-2-(pyridin-4-yl)benzoato-κ5O,O′:O′′,O′′′:O′′′)(1,10-phenanthroline-κ2N,N′)cadmium(II)], C100H60N12O16Cd4
  4. Crystal structure of 2-amino-4-(3,4,5-trimethoxy-phenyl)-7-methyl-5-oxo-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C19H18N2O6
  5. Crystal structure of 1-{4-[(2-hydroxy-5-methyl benzylidene)amino]phenyl}ethanone O-ethyl-oxime, C18H20N2O2
  6. Crystal structure of bis{4-methyl-2-((E)-((4-((E)-1-(ethoxyimino)ethyl)phenyl)imino)methyl)phenolato-κ2N,O)}copper(II), C36H38CuN4O4
  7. Crystal structure of bis{5-methoxy-2-((E)-((4-((E)-1-(methoxyimino)ethyl)phenyl)imino)methyl)phenolato-κ2N,O}nickel(II), C34H34N4NiO6
  8. Crystal structure of poly[μ8-3-carboxyphthalat-κ8-O:O1,O1,O1:O2:O3,O3:O4)silver(I)], C9H4Ag2O6
  9. Crystal structure of 2-((E)-((4-((E)-1-(hydroxyimino)ethyl)phenyl)iminio)methyl)-5-methoxyphenolate, C16H16N2O3
  10. Crystal structure of (E)-1-(4-(((E)-2-hydroxy-3-methoxybenzylidene)amino)phenyl)ethan-1-one oxime, C16H16N2O3
  11. The crystal structure of 2-(tert-butyl)-4-chloro-6-phenyl-1,3,5-triazine, C13H14Cl1N3
  12. Crystal structure of (6,6′-(((((2-aminoethyl)azanediyl)bis(ethane-2,1-diyl))bis(azanylylidene))bis(methanylylidene))bis(2,4-dichlorophenolato)-κ6N,N′,N′′,N′′′,O,O′)cadmium(II) – ethanol – water (1/1/1), C22H28CdCl4N4O4
  13. Crystal structure of 6-chloro-N-methylpyrimidin-4-amine, C5H6ClN3
  14. Synthesis and crystal structure of bis{((E)-((4-((E)-1-(methoxyimino)ethyl)phenyl)imino)methyl)-2-naphtholato-κ2N,O}nickel(II), C40H34N4NiO4
  15. Crystal structure of (E)-2-(4-bromophenyl)ethenesulfonyl fluoride (C8H6BrFO2S)
  16. Synthesis and crystal structure of 2,2′-ethylenedioxybis(benzimide)-2,2′-bis[O-(1-propyloxyamide)]oxime-4,4′,6,6′-tetrachlorodiphenol, C36H34Cl4N4O8
  17. Crystal structure of bis(N-(1-(pyrazin-2-yl)ethylidene)nicotinohydrazonato-κ3N,N′,O)cadmium(II) – methanol (1/1), C26H28N10O4Zn
  18. Crystal structure of diaqua-(N-(1-(pyrazin-2-yl)ethylidene)nicotinohydrazonato-κ3N,N′,O)-bis(nitrato-κ2O,O′)samarium(III), C12H14N7O9Sm
  19. Crystal structure of hexaaqua-{(E)-N′-(1-(pyrazin-2-yl)ethylidene)isonicotinohydrazide-κ3N,N′,O}praseodym(III) trichloride monohydrate, C12H25Cl3N5O8Pr
  20. Crystal structure of methyl 4-(3-cyanophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C21H22N2O3
  21. Crystal structure of ethyl 2-amino-4-(2-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO6
  22. Crystal structure of 2,12-dibromo-5,15-dihexyl-5,15-dihydrobenzo [1,2-b:5,6-c′]dicarbazole, C38H38Br2N2
  23. Crystal structure of ethyl 2-amino-4-(3-hydroxy-4-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO7
  24. Crystal structure of ethyl 2-amino-4-(3,4-dimethylphenyl)-5-oxo-4H,5H-pyrano[3,2-c] chromene-3-carboxylate, C23H21NO5
  25. Crystal structure of 2-hydroxy-N′-(pyrimidin-2-yl)benzohydrazide, C11H10N4O2
  26. Crystal structure of 2-(3,4-dimethylphenyl)-1,8-naphthyridine, C16H14N2
  27. Crystal structure of ethyl 4-(3,4-dimethylphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C23H29NO3
  28. Crystal structure of ethyl 4-(3-cyanophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C22H24N2O3
  29. Crystal structure of 7β,9β-dihydroxy-15-oxo-ent-kauran-16-en-19,6β-olide, C20H26O5
  30. Crystal structure of Ent-7β,20-epoxy-kaur-16-en-1β,6α,7α,14α,15α-pentaol-20-one, C20H30O8
  31. Crystal structure of 1,4-bis(benzo[d][1,3]dioxol-5-ylmethyl)dihydro-1H,3H-furo[3,4-c]furan-3a(4H)-yl acetate, C22H20O8
  32. Crystal structure of methyl 2-((4-((2-nitrophenoxy)methyl)-1H-1,2,3-triazol-1-yl)methyl) benzoate, C18H16N4O5
  33. Crystal structure of diaqua-bis(5-carboxy-1-methyl-1H-imidazole-4-carboxylato-κ2N,O)zinc(II), C12H14N4O10Zn
  34. Hydrothemal synthesis and crystal structure of triaqua-bis(5-carboxy-1-methyl-1H-imidazole-4-carboxylato-κ2N,O1O)manganese(II), C12H16N4O11Mn
  35. Redetermination of methyl 4-(4-chlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C20H22ClNO3
  36. Crystal structure of bis{1-[(benzotriazol-1-yl)methyl]-1-H-1,3-(2-methyl-imdazol)-κN}-dithiocyano-κN-zinc(II) C24H22N12S2Zn
  37. Crystal structure of (5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl furan-2-carboxylate, C10H7FN2O5
  38. Crystal structure of bis(η6-cymene)-tri-μ2-chlorido-ruthenium(II) tetrafluoroborate, C20H28BCl3F4Ru2
  39. Crystal structure of 3,6-diphenyl-7H-[1,2,4]-triazolo[3,4-b][1,3,4]thiadiazine, C16H12N4S
  40. Synthesis and crystal structure of 1,3-bis[(3,4-dicyano)phenoxy]-4,6-dinitro-benzene, C22H8N6O6
  41. Crystal structure of ethyl 2-amino-4-(2,6-dichlorophenyl)-7-methyl-5-oxo-4H,5H-pyrano [4,3-b]pyran-3-carboxylate, C18H15Cl2NO5
  42. Crystal structure of poly[μ3-hydroxy-(μ5-(5-(2-carboxylatophenoxy)isophthalato-κ6O1:O2:O3:O4:O5,O6)-(μ2-1,4-di(1H-imidazol-1-yl)butane-κ2N:N′)dicobalt(II)] hemihydrate, C25H22Co2N4O8.5
  43. Crystal structure of methyl 4-(4-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C20H22BrNO3
  44. Crystal structure of 9,10-dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium 5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate trihydrate, C35H33NO12
  45. Crystal structure of 2,5-bis(4-(10H-phenothiazin-10-yl)phenyl)-1,3,4-oxadiazole, C38H24N4OS2
  46. The crystal structure of (E)-2-(4-hydroxyphenyl)-5-(prop-1-en-1-yl)benzofuran-3-carbaldehyde, C18H14O3
  47. Crystal structure of bis{5H-dibenzo[c,f][1,5]oxabismocin-12(7H)-yl} carbonate, C29H24O5Bi2
  48. Crystal structure of ethyl-5-formyl-3,4-dimethylpyrrole-2-carboxylate — N-(5-ethoxycarbonyl-3,4-dimethylpyrrole)-2-methylene-5-nitrobenzene-1,2-diamine (1:1), C26H31N5O7
  49. Crystal structure of (E)-2-(1-((2-aminophenyl)imino)ethyl)-6-bromo-4-chlorophenol, C14H12BrClN2O
  50. Crystal structure of (Z)-2-(4-chlorophenyl)-4-(furan-2-yl(phenylamino)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one, C21H16ClN3O2
  51. Crystal structure of N2,N4-dibutyl-6-chloro-N2,N4-bis(1,2,2,6,6-pentamethylpiperidin-4-yl)-1,3,5-triazine-2,4-diamine, C31H58ClN7 – Important intermediate of Chimassorb 119 synthesis
  52. Crystal structure of 1-(5-bromo-2-(4-methoxyphenyl)-1H-indol-7-yl)ethanone oxime, C17H15BrN2O2
  53. Crystal structure of poly-{diaqua-bis[(μ2-3-nitrobenzenesulfonylglycine-κ3N:O:O′)(4,4′-bipyridine)manganese(II)]}-dimethylformamide (1/1), C39H35Mn2N9O15S2
  54. Crystal structure of 4-(dimethylamino)-1-(prop-2-yn-1-yl)pyridin-1-ium perchlorate, C10H13ClN2O4
  55. Crystal structure of 2-amino-5-oxo-4-(4-chloro-phenyl)-4,5,6,7-tetrahydro-cyclopenta[b]pyran-3-carbonitrile, C15H11ClN2O2
  56. Crystal structure of triaqua-(pyridine-2,6-dicarboxylato-κ3O,N,O′)cobalt(II) – 6-phenyl-1,3,5-triazine-2,4-diamine (1/1), C16H18CoN6O7
  57. Crystal structure of ethyl 2-amino-4-(3-cyanophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate, C21H22N2O4
  58. Crystal structure of 2-(4-chloro-2,6-dinitrophenyl)-1-(4-chloro-3-nitrophenyl)diazene 1-oxide, C12H5Cl2N5O7
  59. Crystal structure of 3,4-dimethyl-2,6-dinitrophenol, C8H8N2O5
  60. Crystal structure of 1,2-dimethyl-3,5-dinitrobenzene, C8H8N2O4
  61. Crystal structure of ethyl 4-(3-chlorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C21H24ClNO3
  62. Crystal structure of N-(4-chlorophenyl)-2-(2,6-dichlorophenyl)acetamide, C14H10Cl3NO
  63. Crystal structure of 2-amino-4-(4-fluorophenyl)-3-cyano-5-oxo-4H,5H-pyrano[3,2c] chromene, C19H11FN2O3
  64. The crystal structure of (4-nitrophenyl) (5-ferrocenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl) methanone, C21H12F3FeN3O3
  65. Crystal structure of 5,5′-((3-hydroxy-4-methoxyphenyl)methylene)bis(1,3-diethyl-6-hydroxy-2-thioxo-2,3-dihydropyrimidin-4(1H)-one), C24H30N4O6S2
  66. Crystal structure of (3aR,4R,5R,7R,8S,9R,9aS,12R)-7-ethyl-5-(1-hydroxy-2-((R)-3-hydroxypyrrolidin-1-yl)ethoxy)-4,7,9,12-tetramethyldecahydro-4,9a-propanocyclopenta[8]annulene-3,8-diol – a pleuromutilin derivative, C26H41NO5
  67. Crystal structure of bis(μ2-3-formyl-5-methoxy-2-oxidobenzoato-κ3O,O′:O′)-hexapyridine-dicadmium(II) – pyridine (1/1), C53H47Cd2N7O10
  68. Crystal structure of ethyl 2-amino-4-(3-methoxyphenyl)-5-oxo-4H,5H-pyrano[3,2-c]chromene-3-carboxylate, C22H19NO6
  69. Crystal structure of methyl 4-(3,5-ditrifluoromethylphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate — water (2/1), C22H21F6NO3
  70. Crystal structure of 2-(4-bromophenyl)-2,3-dihydro-1H-perimidine, C17H13BrN2
  71. Crystal structure of (5-ethyl-2-(4-methoxyphenyl)-1,3-dioxan-5-yl)methanol, C14H20O4
  72. Crystal structure of (E)-N-(4-bromo-2-(1-(hydroxyimino)ethyl)phenyl)benzamide, C15H13BrN2O2
  73. Crystal structure of caffeinium triiodide – caffeine (1/1), C16H21I3N8O4
  74. Crystal structure of methyl 2-methyl-4-(3-methoxyphenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C19H21NO4
  75. Crystal structure of (E)-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-phenylprop-2-en-1-one, C23H28O2
  76. Crystal structure of 1,4-bis(2-azidoethyl)piperazine-1,4-diium dichloride, C8H18N8Cl2
  77. The crystal structure of dichlorido-(1,3-bis(2,6-dimethylphenyl)-1H-imidazol-2(3H)-ylidene)-(morpholine-κ1N)palladium(II), C23H29Cl2N3OPd(II)
  78. The crystal structure of 1-((5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-yl)methyl)-1,3-diphenylurea, C24H21ClN4O
  79. Crystal structure of 6-(2-bromoacetamido)tetrahydro-2H-pyran-2,3,4,5-Tetrayl tetraacetate, C16H22BrNO10
  80. Crystal structure of 5-methylpyrazine-2-carbohydrazide, C6H8N4O
  81. Crystal structure of catena-poly[(μ2-5-(tert-butyl)isophthalato-κ4O,O′:O′′,O′′′)(-4′-(pyridin-4-yl)-2,2′:6′,2′′-terpyridine-κ3N,N′,N′′)manganese(II)], C32H28N4O5Mn
Heruntergeladen am 17.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2018-0049/html
Button zum nach oben scrollen